Nexstim logo

NEXSTIM PLC PUBLISHES 2014 ANNUAL REPORT

09 March 2015

Nexstim Plc (NXTMH:HEX, NXTMS:STO), a medical technology company aiming to improve rehabilitation for stroke patients through the use of non-invasive brain stimulation, announces the publication of its 2014 Annual Report. These documents are available on the “Investor Relations” section of the Company's website at www.nexstim.com.

The Annual Report contains the Report of the Board of Directors, the Financial Statements and Consolidated Financial Statements and the Auditor's Report.

A copy of the Annual Report can be found here.

Nexstim Plc

Janne Huhtala, CEO

  

For further information please visit www.nexstim.com or contact:

 Nexstim                                                                                                                               +358 (0)40 8615046

Janne Huhtala, Chief Executive Officer                                                                        janne.huhtala@nexstim.com

UB Capital Oy (Certified Adviser)                                                                                     +358 (0)9 2538 0225

Consilium Strategic Communications                                                                              +44 (0)20 3709 5700

Mary-Jane Elliott / Ivar Milligan                                                                        nexstim@consilium-comms.com

  

About Nexstim Plc

Nexstim, formed in 2000 and based in Finland, is a medical technology company aiming to improve rehabilitation for stroke patients. Nexstim has pioneered its technology in brain diagnostics with the Navigated Brain Stimulation (NBS) system as the first and only FDA-cleared and CE-marked navigated Transcranial Magnetic Stimulation (nTMS) device for pre-surgical mapping of the motor and speech cortices. Based on the same technology platform, the company has developed a device for stroke therapy called Navigated Brain Therapy (NBT®). In H1 2014, Nexstim initiated a two-year pivotal Phase III study at 12 sites in the US aiming to demonstrate the effectiveness of NBT® and gain FDA clearance for commercialisation in post-acute stroke therapy in the US. Nexstim's shares are listed on Nasdaq First North Finland and Nasdaq First North Sweden. For more information please visit www.nexstim.com.

Back to Press Releases